Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications.
It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.38 Decreased by -72.73% | -0.20 Decreased by -90.00% |
| Mar 19, 24 | -0.25 Decreased by -725.00% | -0.04 Decreased by -525.00% |
| Nov 13, 23 | -0.13 Increased by +45.83% | 0.04 Decreased by -425.00% |
| Aug 9, 23 | -0.14 Increased by +39.13% | -0.04 Decreased by -250.00% |
| May 11, 23 | -0.22 Decreased by -833.33% | -0.05 Decreased by -340.00% |
| Mar 23, 23 | 0.04 Increased by +114.81% | -0.12 Increased by +133.33% |
| Nov 14, 22 | -0.24 Increased by +22.58% | -0.01 Decreased by -1.70 K% |
| Aug 9, 22 | -0.23 Decreased by -155.56% | -0.01 Decreased by -2.20 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 34.27 M Increased by +50.13% | -4.39 M Increased by +32.07% | Decreased by -12.81% Increased by +54.75% |
| Jun 30, 23 | 33.47 M Increased by +43.51% | -4.23 M Increased by +32.22% | Decreased by -12.64% Increased by +52.77% |
| Mar 31, 23 | 26.10 M Increased by +18.01% | -6.64 M Decreased by -188.95% | Decreased by -25.45% Decreased by -144.86% |
| Dec 31, 22 | 20.33 M Increased by +0.70% | 1.05 M Increased by +114.22% | Increased by +5.19% Increased by +114.12% |
| Sep 30, 22 | 22.82 M Increased by +21.98% | -6.46 M Increased by +22.38% | Decreased by -28.32% Increased by +36.37% |
| Jun 30, 22 | 23.32 M Increased by +28.61% | -6.24 M Decreased by -151.78% | Decreased by -26.75% Decreased by -95.76% |
| Mar 31, 22 | 22.12 M Increased by +43.24% | -2.30 M Decreased by -1.16 K% | Decreased by -10.39% Decreased by -839.65% |
| Dec 31, 21 | 20.19 M Increased by +38.32% | -7.42 M Decreased by -745.60% | Decreased by -36.74% Decreased by -566.74% |